About Trivalent Therapeutics

Our Mission

Trivalent Therapeutics LLC is a Dallas-based intellectual property company dedicated to advancing novel pharmacological approaches to alcohol use disorder (AUD) — a condition affecting tens of millions of people yet served by only a handful of approved medications.

We believe the next generation of AUD therapy lies in the metabolic-reward axis. Our work centers on retatrutide, a triple agonist of the GLP-1, GIP, and glucagon receptors, and the methods by which it can reduce craving, relapse, and heavy alcohol consumption.

Our Approach

Rather than developing drugs in-house from end to end, Trivalent concentrates on what it does best: identifying differentiated mechanisms of action, securing robust patent protection around them, and partnering with pharmaceutical companies positioned to bring those methods through clinical development and to market.

This model lets clinical-stage partners build on a defensible foundation of intellectual property while accelerating the path from concept to patient.

The Science

Retatrutide's simultaneous engagement of three incretin pathways distinguishes it from earlier single- and dual-agonist agents such as semaglutide and tirzepatide. By modulating central reward signaling alongside metabolic effects, the molecule offers a uniquely broad mechanism for addressing the neurobiology of addiction — including in combination with established agents such as naltrexone.